Subcutaneous Administration of a Depot Gonadotropin-Releasing Hormone Agonist Induces Profound Reproductive Axis Suppression in Women
Authors:
- Marco FilicoriMFMarco Filicori
- Graciela E CognigniGCGraciela E Cognigni
- Rossella ArnoneRARossella Arnone
- Patrizia PocognoliPPPatrizia Pocognoli
- Cristina TabarelliCTCristina Tabarelli
- Walter CiampagliaWCWalter Ciampaglia
- Stefania TaraborelliSTStefania Taraborelli
- Paolo CasadioPCPaolo Casadio
- 1 March 1998
- journal article
- clinical trial
- Published by Elsevier in Fertility and Sterility
- Vol. 69 (3) , 443-449
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Endometriosis: Leuprolide in a 3-monthly versus a monthly depot formulation for the treatment of symptomatic endometriosis: a pilot studyHuman Reproduction, 1996
- The GnRH challenge test: a quantitative measure of pituitary desensitization during GnRH agonist administrationClinical Endocrinology, 1996
- Gonadotrophin-Releasing Hormone AgonistsDrugs, 1994
- Pituitary responsiveness after administration of a GnRH agonist depot formulation: Decapeptyl CRClinical Endocrinology, 1993
- RANDOMISED CONTROLLED STUDY OF ORCHIDECTOMY VS LONG-ACTING D-TRP-6-LHRH MICROCAPSULES IN ADVANCED PROSTATIC CARCINOMAThe Lancet, 1985
- Biodegradable polymers for the sustained release of peptidesBiochemical Society Transactions, 1985
- Long-acting delivery systems for peptides: inhibition of rat prostate tumors by controlled release of [D-Trp6]luteinizing hormone-releasing hormone from injectable microcapsules.Proceedings of the National Academy of Sciences, 1984
- Controlled Release of a Luteinizing Hormone-Releasing Hormone Analogue from Poly(d,l-lactide—co-glycolide) MicrospheresJournal of Pharmaceutical Sciences, 1984